Cargando…

Clinical Toxicities of Histone Deacetylase Inhibitors

The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Subramanian, Srividya, Bates, Susan E., Wright, John J., Espinoza-Delgado, Igor, Piekarz, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096/
https://www.ncbi.nlm.nih.gov/pubmed/27713375
http://dx.doi.org/10.3390/ph3092751
_version_ 1782317930607804416
author Subramanian, Srividya
Bates, Susan E.
Wright, John J.
Espinoza-Delgado, Igor
Piekarz, Richard L.
author_facet Subramanian, Srividya
Bates, Susan E.
Wright, John J.
Espinoza-Delgado, Igor
Piekarz, Richard L.
author_sort Subramanian, Srividya
collection PubMed
description The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae.
format Online
Article
Text
id pubmed-4034096
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40340962014-05-27 Clinical Toxicities of Histone Deacetylase Inhibitors Subramanian, Srividya Bates, Susan E. Wright, John J. Espinoza-Delgado, Igor Piekarz, Richard L. Pharmaceuticals (Basel) Review The HDAC inhibitors are a new family of antineoplastic agents. Since the entry of these agents into our therapeutic armamentarium, there has been increasing interest in their use. Although this family comprises chemical compounds from unrelated chemical classes that have different HDAC isoform specificities, they surprisingly have very similar toxicity profiles. In contrast, the observed toxicity profile is somewhat different from that of traditional cytotoxic chemotherapeutic agents and from other epigenetic agents. While some of the side effects may be familiar to the oncologist, others are less commonly seen. As some patients remain on therapy for a prolonged period of time, the long-term sequelae need to be characterized. In addition, since preclinical models suggest promising activity when used in combination with other antineoplastic agents, combination trials are being pursued. It will thus be important to distinguish the relative toxicity attributed to these agents and be alert to the exacerbation of toxicities observed in single agent studies. Notably, few of the agents in this class have completed phase 2 testing. Consequently, more clinical experience is needed to determine the relative frequency of the observed side effects, and to identify and develop approaches to mitigate potential clinical sequelae. MDPI 2010-08-26 /pmc/articles/PMC4034096/ /pubmed/27713375 http://dx.doi.org/10.3390/ph3092751 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Subramanian, Srividya
Bates, Susan E.
Wright, John J.
Espinoza-Delgado, Igor
Piekarz, Richard L.
Clinical Toxicities of Histone Deacetylase Inhibitors
title Clinical Toxicities of Histone Deacetylase Inhibitors
title_full Clinical Toxicities of Histone Deacetylase Inhibitors
title_fullStr Clinical Toxicities of Histone Deacetylase Inhibitors
title_full_unstemmed Clinical Toxicities of Histone Deacetylase Inhibitors
title_short Clinical Toxicities of Histone Deacetylase Inhibitors
title_sort clinical toxicities of histone deacetylase inhibitors
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4034096/
https://www.ncbi.nlm.nih.gov/pubmed/27713375
http://dx.doi.org/10.3390/ph3092751
work_keys_str_mv AT subramaniansrividya clinicaltoxicitiesofhistonedeacetylaseinhibitors
AT batessusane clinicaltoxicitiesofhistonedeacetylaseinhibitors
AT wrightjohnj clinicaltoxicitiesofhistonedeacetylaseinhibitors
AT espinozadelgadoigor clinicaltoxicitiesofhistonedeacetylaseinhibitors
AT piekarzrichardl clinicaltoxicitiesofhistonedeacetylaseinhibitors